New Study in The Journal of Foot and Ankle Surgery Shows Significant Advantages of Nextremity Solutions, Inc. Hammertoe Device Over Kirschner Wires
WARSAW, Ind., May 16, 2016 (GLOBE NEWSWIRE) — An article now in press in The Journal of Foot and Ankle Surgery entitled, “Dual-Component Intramedullary Implant Versus Kirschner Wire for Proximal Interphalangeal Joint Fusion: A Randomized Controlled Clinical Trial,” shows significant advantages of using the Nextra® Hammertoe Correction System as opposed to using traditional Kirschner Wires (K-wires) for the treatment of hammertoe deformity.
The Nextra® device is a two-piece implant developed by Nextremity Solutions, Inc., a pure-play foot and ankle orthopedic company located in Warsaw, IN. This device differed from K-wires by achieving more than a 5x higher rate of bone fusion. Additionally, the Nextra® implant exhibited an 84% fusion rate, compared to just 16% with K-wires.
“Some of the issues with the utilization of K-wires in hammertoe surgery are a lack of fusion, lack of rotational stability, risk of infection with post-operative K-Wire exposure, and poor patient satisfaction. According to the study, patients with the Nextra implant not only had drastic improvements in fusion rates but also experienced greater pain relief, a decrease in disability and an increase in activity levels. Simply put, the Nextra patients had greater patient satisfaction outcomes. These clinically proven results help to redefine the standard of care for hammertoe patients,” said Mike Coon, Executive Director of Sales & Marketing for Nextremity Solutions, Inc.
Executive Director of Product Development for Nextremity Solutions, Ryan Schlotterback, commented, “This study is a great example of our commitment to proving the clinical efficacy and benefits of our products and technology. Nextremity Solutions will continue to work with our surgeon partners to develop innovative solutions with improved and proven clinical outcomes. We are steadfast in our belief that the foot and ankle market is primed for continued advancements that lead to better surgical outcomes and patient satisfaction.”
The surgeons involved in this randomized controlled clinical trial are Richard M. Jay, DPM, FACFAS, D. Scot Malay, DPM, MSCE, FACFAS, Adam S. Landsman, DPM, PhD, FACFAS, Nathan Jennato, DPM, James Huish, DPM, and Melissa Younger, DPM. The study is available to subscribers of the jounal now at the following link and will be available soon in the printed journal: http://www.jfas.org/article/S1067-2516%2816%2900152-6/abstract.
About Nextremity Solutions, Inc.
Nextremity Solutions, Inc. is a privately held medical device company offering innovative solutions and approaches to foot and ankle surgical intervention. The Company’s procedure-ready, sterile implant systems for the correction of foot and ankle pathologies include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.
CONTACT: For further information, visit www.nextremitysolutions.com or call Dave Temple, Director of Marketing & Corporate Communications at 574-635-3022.
